cancer immunotherapycell therapydrug deliveryimmune checkpoint blockadenanomedicineIn article number 1707112, Peng Huang, Zhen Gu, and co﹚orkers engineer cellular nanovesicles presenting PDreceptors on their membranes, which enhance antitumor response by disrupting the PD/PD㎜1 immune inhibitory axis. ...
DETERMINANTS OF CANCER RESPONSE TO IMMUNOTHERAPY BY PD-1 BLOCKADEMolecular determinants of cancer response to immunotherapy are described, as are systems and tools for identifying and/or characterizing cancers likely to respond to immunotherapy.CHAN, TimothyWOLCHOK, Jedd...
Immunotherapy targeting programmed cell death-1 (PD-1) and PD-L1 immune checkpoints has reshaped treatment paradigms across several cancers, including breast cancer. Combining PD-1/PD-L1 immune checkpoint blockade (ICB) with chemotherapy has shown promising efficacy in both early and metastatic tripl...
The PD-L1/PD-1 signaling pathway is the gold standard for cancer immunotherapy. Therapeutic antibodies targeting PD-1, such as nivolumab (Opdivo) and pembrolizumab (Keytruda), and PD-L1, including atezolizumab (Tecentriq), durvalumab (Imfinzi), and avelumab (Bavencio) have received Food and ...
Iwai Y, Ishida M, Tanaka Y et al (2002) Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc Natl Acad Sci USA 99:12293–12297 ArticleCASPubMedPubMed CentralGoogle Scholar ...
Immunotherapy targeting programmed cell death-1 (PD-1) and PD-L1 immune checkpoints has reshaped treatment paradigms across several cancers, including breast cancer. Combining PD-1/PD-L1 immune checkpoint blockade (ICB) with chemotherapy has shown promising efficacy in both early and metastatic tripl...
Cancer immunotherapies, represented by immune checkpoint inhibitors (ICIs), have reshaped the treatment paradigm for both advanced non-small cell lung cancer and small cell lung cancer. Programmed death receptor-1/programmed death receptor ligand-1 (PD-1
cytotoxic drugs; DNA damage response; immunotherapy; programmed death ligand-1 (PD-L1) 1. Introduction Surgery, chemotherapy, and radiation therapy constitute the main approaches to cancer treatment. One alternative way of targeting cancer concentrates on boosting the patient’s immune system so that ...
PD-1Digestive cancersCheckpoint blockadeImmunotherapyResistance to chemotherapy is a major obstacle in the effective treatment of cancer patients. B7-homolog 1,... VDK Lauren,G Goel,K Ramanan,... - 《Journal for Immunotherapy of Cancer》 被引量: 13发表: 2016年 Cross-talk between TNF-α and ...
An immune attack against tumour cells in the host mediated by transplanted allogeneic T cells. Allogeneic Cells from a different individual that express different MHC alleles. About this article Cite this article Pardoll, D. The blockade of immune checkpoints in cancer immunotherapy.Nat Rev Cancer12...